VALIDOGENRecombinant protein production in Pichia typically relies on AOX1 promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.
Tebubio SASMessenger RNA (mRNA) has gained significant attention since being used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. mRNA holds potential for preventing and treating many difficult-to-treat or genetic diseases, including cancers. However, its production is complex and raises challenges for researchers developing new therapies: Discover Tebubio.
Jeremy Levin, Ovid TherapeuticsThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.
At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.
Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly increased its manufacturing capacities for biopharmaceutical products at its production site in Bovenau, Germany.
The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMOs services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.